rhTPO Dose Escalation vs Eltrombopag Switch in ITP

This study is a prospective, multicenter, randomized controlled study, planning to enroll 110 ITP patients who failed to respond to conventional-dose rhTPO (300 IU/kg/d) after 14 days of treatment (PLT \< 30×10⁹/L). After a 2-week washout period, they will be randomized to the rhTPO double-dose group (Group A) and EPAG-pfos group (Group B), with blood routine monitored weekly and doses adjusted according to platelet levels, comparing the response rates of the two groups at 6 weeks after switching treatment.

NCT Number	NCT07476846
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Primary Immune Thrombocytopenia (ITP)
Enrollment	112 participants
Start Date	2026-06
Primary Completion	2027-12 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-01